Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.17 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $34.36 million versus the consensus estimate of $8.01 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
• JPM identifies consumer sectors to buy for a 2H rebound
• Alan Greenspan, influential former Federal Reserve chair, dies at 100